01:27 PM EDT, 05/14/2025 (MT Newswires) -- AbbVie ( ABBV ) said Wednesday that the US Food and Drug Administration granted accelerated approval for Emrelis for treatment of patients with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression.

The drug is authorized for adults who have received a prior systemic therapy, according to the company.

AbbVie ( ABBV ) said the approval of Emrelis is based on overall response rate and duration of response and continued approval is conditional on clinical benefit verified in confirmatory trials.

Shares of the company were down 4.2% in recent trading.

Price: 179.84, Change: -8.16, Percent Change: -4.34